£12.0M
The financing round was led by Pfizer Ventures and accompanied by pro-rata contributions from existing investors.
Mission Therapeutics
Mission Therapeutics discovers and develops selective inhibitors for deubiquitylating enzymes.
£12.0MTotal raised
Mission Therapeutics is a drug discovery and development company based in Cambridge that focuses on selectively inhibiting deubiquitylating enzymes. The firm targets the ubiquitin pathway to address conditions such as kidney disease, fibrosis, and neurodegenerative disorders.
Filed accounts
Shareholders' funds
Members only
Profit for the year
Members only
Employees
Members only
Cash, assets and headcount from Mission Therapeutics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
Categories
Team
AL
Anker Lundemose
Chief Executive Officer